



News Release

December 15, 2015

Maruho Co., Ltd.

Maruho to Dissolve UK Subsidiary

Osaka (Japan), December 15, 2015 – Maruho Co., Ltd. (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces that it will dissolve its consolidated subsidiary in the United Kingdom, Maruho Europe Ltd. (“MEL”, Office: London, UK, Managing Director: Junichi Hamada).

1. Reasons for the Dissolution

Maruho established MEL in 2012 for the purpose of managing clinical trials and collecting information in Europe. All planned operations have been completed, therefore, Maruho has decided to dissolve MEL.

2. Subsidiary Profile

(1) Company Name	Maruho Europe Ltd.
(2) Address	200 Shepherd's Bush Road, Hammersmith, London, W6 7NL, UK
(3) Managing Director	Junichi Hamada
(4) Business Activities	Development of pharmaceuticals
(5) Paid-In Capital	£800,000.00
(6) Date Founded	April 2012
(7) Fiscal Year End	September 30
(8) Major Shareholders (shareholding ratio)	Maruho Co., Ltd. (100%)

3. Settlement Schedule

Settlement is scheduled to be completed by the end of 2016.

4. Effect on Business Results

The effect of the settlement on Maruho's consolidated financial results will be minor.

5. Note:

In Europe, Maruho Deutschland GmbH (Office: Leverkusen, Germany, Managing Director: Junichi Hamada) continues its pharmaceutical business development activities as normal.